BioPharmSignal logoBioPharmSignal

Biotech News

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

Ultragenyx Pharmaceutical (RARE)Ultragenyx PharmaceuticalCompany update

Agreement marks the Company’s second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction Agreement marks the Company’s second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction

Related news

RAREUltragenyx Pharmaceutical2026-10-07 12:30 EST

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

RAREUltragenyx Pharmaceutical2026-07-08 13:08 EST

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact

RHHBYRoche Holdings AG2026-09-10 05:00 EST

U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments

AGIOAgios Pharmaceuticals, Inc.2026-07-07 11:00 EST

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

MNPRMonopar2026-06-30 12:00 EST

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

BDRXBiodexa Pharmaceuticals2026-09-15 12:00 EST

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds

ARWRArrowhead Pharmaceuticals2026-08-04 20:00 EST

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

RHHBYRoche Holdings AG2026-10-16 05:00 EST

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

ETONEton Pharmaceuticals2026-10-14 10:50 EST

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

RCKTRocket Pharmaceuticals2026-10-07 13:36 EST

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

View all latest news

Ultragenyx Pharmaceutical

Rare-Disease Portfolio Ultragenyx Pharmaceutical develops and commercializes therapies for serious rare and ultrarare genetic diseases. Its portfolio spans antisense oligonucleotides, enzyme and small-molecule medicines, and adeno-associated virus gene therapies. GTX-102 for Angelman Syndrome GTX-102, or apazunersen, is an antisense...

Recent company news

RAREUltragenyx Pharmaceutical2026-10-14 12:30 EST

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

RAREUltragenyx Pharmaceutical2026-10-07 12:30 EST

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

RAREUltragenyx Pharmaceutical2026-10-02 06:00 EST

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

RAREUltragenyx Pharmaceutical2026-09-17 19:48 EST

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

RAREUltragenyx Pharmaceutical2026-09-02 20:01 EST

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

Stock data

Close
15.92 USD
Market cap
2.15B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States